FBLG · FibroBiologics, Inc.
$0.84
-0.01 (-0.60%)
At close · Jul 17
Going-concern doubt
— flagged Apr 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Apr 30, 2026
Market Cap
$4.35M
Shares
5,208,915
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Pete O’Heeron | CEO | $1,066,191 |
| Hamid Khoja | Chief Scientific Officer | $654,070 |
| Ruben A. Garcia | General Counsel | $626,800 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| General Counsel | — | $2,752,843 |
| Ruben A. Garcia | General Counsel | $2,752,843 |
| Pete O’Heeron | CEO | $1,805,199 |
| Hamid Khoja | Chief Scientific Officer | $853,646 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Pete O’Heeron | CEO | $4,286,308 |
| Mark Andersen | CFO | $1,329,808 |
| Hamid Khoja | Chief Scientific Officer | $1,307,758 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Pete O’Heeron | CEO | $922,485 |
| Hamid Khoja | Chief Scientific Officer | $497,609 |
| Mark Andersen | CFO | $379,438 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kathleen Rubins | Class III director | Appointed | 2026-07-09 |